Biomarkers for Immunotherapy of Cancer - read free eBook in online reader or directly download on the web page. Select files or add your book in reader. Download and read online ebook Biomarkers for Immunotherapy of Cancer write by Magdalena Thurin. This book was released on 2019-09-10. Biomarkers for Immunotherapy of Cancer available in PDF, EPUB and Kindle. This book provides the immune oncology (IO) community with a deeper understanding of the scope of the biomarker methods to potentially improve the outcome from immunotherapy. The editors secured the input from experts in the field dedicated to translating scientific research from bench to bedside was submitted. The book provides not only details about the technical, standardization and interpretation aspects of the methods but also introduces the reader to the background information and scientific justification for selected biomarkers and assays. Written in the highly successful Methods in Molecular Biology series format, chapters include introductions to their respective topics, lists of the necessary materials and reagents, step-by-step, readily reproducible laboratory protocols, and tips on troubleshooting and avoiding known pitfalls.
Dynamic Biomarkers of Response to Anti-Immune Checkpoint Inhibitors in Cancer
Dynamic Biomarkers of Response to Anti-Immune Checkpoint Inhibitors in Cancer - read free eBook in online reader or directly download on the web page. Select files or add your book in reader. Download and read online ebook Dynamic Biomarkers of Response to Anti-Immune Checkpoint Inhibitors in Cancer write by Said Dermime. This book was released on 2021-12-28. Dynamic Biomarkers of Response to Anti-Immune Checkpoint Inhibitors in Cancer available in PDF, EPUB and Kindle.
Identification of Biomarkers for Cancer Immunotherapy: From Bench to Bedside, volume I
Identification of Biomarkers for Cancer Immunotherapy: From Bench to Bedside, volume I - read free eBook in online reader or directly download on the web page. Select files or add your book in reader. Download and read online ebook Identification of Biomarkers for Cancer Immunotherapy: From Bench to Bedside, volume I write by Chang Gu. This book was released on 2023-10-20. Identification of Biomarkers for Cancer Immunotherapy: From Bench to Bedside, volume I available in PDF, EPUB and Kindle. During the past few decades, immunotherapy has become an established pillar of cancer treatment improving the survival of numerous patients with diverse solid and hematologic tumors. The leading causes behind the success are the discovery of immune checkpoint inhibitors (ICIs) and the development of chimeric antigen receptor (CAR) T/M/NK cells. As for ICIs, malignancies take advantage of the inhibitory programmed cell death protein 1/programmed cell death protein ligand 1 (PD-1/PD-L1) or cytotoxic T-lymphocyte-associated protein (CTLA-4) pathways to evade the immune system, and disruption of the axis by immune checkpoint inhibitors can achieve durable disease remissions, which has been proved by basic researches and (pre-) clinical studies among lung cancer, melanoma, renal cell cancer, head, and neck squamous cell carcinoma, urothelial cancer, and Hodgkin’s disease. However, the 5-year survival rate of patients treated with ICIs varies with each individual and also relies on tumor specific pathological or molecular subtypes. Besides, the efficacy of ICIs is still limited in terms of drug resistance and fewer potential responders. Thus, there is a big challenge to identify and develop more novel reliable ICIs, as well as sensibilize existing ICIs for patients with drug resistance or even for non-responders.
Community Series in Novel Biomarkers for Predicting Response to Cancer Immunotherapy, volume II
Community Series in Novel Biomarkers for Predicting Response to Cancer Immunotherapy, volume II - read free eBook in online reader or directly download on the web page. Select files or add your book in reader. Download and read online ebook Community Series in Novel Biomarkers for Predicting Response to Cancer Immunotherapy, volume II write by . This book was released on 2024-01-10. Community Series in Novel Biomarkers for Predicting Response to Cancer Immunotherapy, volume II available in PDF, EPUB and Kindle. This Research Topic is the second volume of the “Community Series in Novel Biomarkers for Predicting Response to Cancer Immunotherapy". Please see Volume I here. Immunotherapy has revolutionized the treatment of malignancies. Targeting of immune checkpoints cytotoxic T-lymphocyte-associated protein 4, programmed cell death protein 1 (PD-1) and its ligand (PD-L1) has led to improving survival in a subset of patients. Despite their remarkable success, clinical benefit remains limited to only a subset of patients. A significant limitation behind these current treatment modalities is an irregularity in clinical response, which is especially pronounced among checkpoint inhibition. Currently, relevant predictors of cancer immunotherapy response include microsatellite instability-high/deficient mismatch repair (MSI-H/dMMR), expression of PD-L1, tumor mutation burden (TMB), immune genomic characteristics, and tumor infiltrating lymphocytes (TILs). However, none of them have sufficient evidence to be a stratification factor. Moreover, as the combined strategies for effective cancer immunotherapy had been developed in multiple tumors, such as Immunotherapy combined with chemotherapy, radiotherapy, targeted therapy and anti-angiogenesis therapy. Therefore, the development of novel biomarkers endowed with high sensitivity, specificity and accuracy able to identify which patients may truly benefit from the treatment with cancer immunotherapy would allow to refine the therapeutic selection and to better tailor the treatment strategy. This research topic aims to focus on the advances in the discoveries of novel biomarkers for predicting response to cancer immunotherapy in various tumors. We welcome the submission of original research and review articles that include biomarkers in clinical study and applications, as well as technologies or discoveries in experimental approaches.
Novel biomarkers in tumor immunity and immunotherapy
Novel biomarkers in tumor immunity and immunotherapy - read free eBook in online reader or directly download on the web page. Select files or add your book in reader. Download and read online ebook Novel biomarkers in tumor immunity and immunotherapy write by Takaji Matsutani. This book was released on 2024-07-26. Novel biomarkers in tumor immunity and immunotherapy available in PDF, EPUB and Kindle. Immune checkpoint inhibitors (ICIs) such as anti-PD-1 and anti-PD-L1 antibodies are highly effective against many types of cancer, yet durable responses are limited to a subset of patients highlighting the need for the development of effective biomarkers to predict prognosis and efficacy. Currently, PD-L1 expression in tumors, microsatellite instability (MSI) or mismatch repair deficiency (dMMR), and tumor mutation burden (TMB) are known as biomarkers for cancer immunotherapy but are not sufficient. Combination therapy with immune checkpoint inhibitors and chemotherapy or radiation therapy, as well as diverse therapies targeting intra-tumoral regulatory T cells have been described, but there are currently no unifying biomarkers that are applicable to clinically, a simple, fast, non-invasive method that can yield biomarkers of disease with a minimal adverse effect on patients is desirable. Recent findings suggest that the balancing of effector T cells and regulatory cells in the tumor microenvironment is associated with cancer progression and prognosis. Cells and molecules involved in the control of cancer are complex, and a better understanding of the tumor immune environment will lead to the development of truly effective biomarkers. This topic will focus on novel biomarkers that predict efficacy, prognosis, or the development of adverse events in various cancer immunotherapies, and extensive basic research leading to the development of biomarkers. Manuscripts consisting solely of bioinformatics or computational analysis of public genomic or transcriptomic databases which are not accompanied by robust and relevant validation (clinical cohort or biological validation in vitro or in vivo) are out of scope for this topic. We expect a wide range of research, not only in serology, genetics, and immunocytochemistry but also in bacterial flora. Research on the development of novel assays and bioinformatics methods is also welcome: • Non-invasive biomarkers for cancer immunotherapy. • Bulk RNA-seq, scRNA-seq, or Rep-seq methods. • Correlation of tumor immune cells with gut microbiota in tumor immunotherapy. • Impact of Teff and Treg balance in the tumor microenvironment on tumor prognosis. • Inflammatory and immune signatures associated with drug response versus resistance in cancer.
